Penn Medicine Abramson Cancer Center


 

ASH 2019 Update on Novel Therapies for Higher Risk MDS: IDH Inhibitors, Azacitidine Combinations (Ven+Aza & Magrolimab+Aza), Targeting TP53 Mutations

12 views
February 24, 2020
0 Comments
Login to view comments. Click here to Login